Programmed Death-Ligand (PD-L1), Epidermal Growth Factor (EGF), Relaxin, and Matrix Metalloproteinase-3 (MMP3): Potential Biomarkers of Malignancy in Canine Mammary Neoplasia.
Makchit GaladimaMariana TelesJosep PastorJavier Hernández-LosaJoan-Enric Rodríguez-GilMaria Montserrat Rivera Del AlamoPublished in: International journal of molecular sciences (2024)
Gene expression has been suggested as a putative tool for prognosis and diagnosis in canine mammary neoplasia (CMNs). In the present study, 58 formalin-fixed paraffin-embedded (FFPE) paraffined canine mammary neoplasias from 27 different bitches were included. Thirty-seven tumours were classified as benign, whereas thirty-one were classified as different types of canine carcinoma. In addition, mammary samples from three healthy bitches were also included. The gene expression for vascular endothelial growth factor-α ( VEGFα ), CD20 , progesterone receptor ( PGR ), hyaluronidase-1 ( HYAL-1 ), programmed death-ligand 1 ( PD-L1 ), epidermal growth factor ( EGF ), relaxin ( RLN2 ), and matrix metalloproteinase-3 ( MMP3 ) was assessed through RT-qPCR. All the assessed genes yielded a higher expression in neoplastic mammary tissue than in healthy tissue. All the evaluated genes were overexpressed in neoplastic mammary tissue, suggesting a role in the process of tumorigenesis. Moreover, PD-L1, EGF, relaxin, and MMP3 were significantly overexpressed in malignant CMNs compared to benign CMNs, suggesting they may be useful as malignancy biomarkers.